---
title: "Low‑Dose Epirubicin in Sepsis and Septic Shock: Phase IIa EPOS‑1 Safety and Dose‑Escalation Results"
id: "medrxiv-1-epirubicin-for-the-treatment-of-sepsis-and-septic-shock-epos-1-a-randomized"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-epirubicin-for-the-treatment-of-sepsis-and-septic-shock-epos-1-a-randomized"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1?rss=1"
published_at: "2026-08-25T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Low‑Dose Epirubicin in Sepsis and Septic Shock: Phase IIa EPOS‑1 Safety and Dose‑Escalation Results
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-epirubicin-for-the-treatment-of-sepsis-and-septic-shock-epos-1-a-randomized
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1?rss=1)
- **Published At:** 2026-08-25T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The EPOS‑1 trial tested whether **low‑dose epirubicin** can be safely administered to patients with **sepsis** and **septic shock**, building on preclinical data that anthracyclines may enhance disease tolerance to infection. - This was a randomized, double‑blind, placebo‑controlled, phase IIa dose‑escalation study conducted at five German university hospitals and registered as NCT05033808. - Eligible adult patients met Sepsis‑3 criteria and were enrolled within 48 hours of diagnosis; the first patient was enrolled on October 19, 2022, and last follow‑up occurred May 21, 2025. - Participants were randomized in a 4:1 ratio (epirubicin:placebo). The epirubicin arm received a single intravenous dose at one of three dose levels across consecutive phases: **3.75 mg/m2**, **7.5 mg/m2**, or **15 mg/m2**. - The trial’s primary endpoint was **14‑day myelotoxicity**; secondary and exploratory outcomes included 90‑day mortality, organ dysfunction assessed by **SOFA** score, pharmacokinetic/pharmacodynamic (PK/PD) modelling, and cytokine release assessments. - Of 854 patients screened, 32 were randomized and 31 were included in the primary analysis: 6 placebo, 9 at 3.75 mg/m2, 9 at 7.5 mg/m2, and 8 at 15 mg/m2. - No myelotoxicity was observed in any treatment group during the 14‑day primary observation window. - There were no significant differences between groups in 90‑day mortality or SOFA scores as reported; details of statistical comparisons were provided in the source. - A total of 39 serious adverse events (SAEs) occurred in the epirubicin group; investigators judged two of these as possibly related to epirubicin. - PK/PD and cytokine results are listed as measured outcomes, but the source did not report detailed findings in the abstract. - The trial received ethical approval from Jena University Hospital and German health authority (BfArM) approvals; funding was declared from the Bundesministerium für Forschung, Technologie und Raumfahrt. - One author disclosed a related patent on anthracyclines for sepsis treatment; other authors reported no competing interests. - The authors conclude low‑dose epirubicin was not associated with increased **myelotoxicity** in this small, randomized phase IIa cohort, supporting further investigation but not demonstrating efficacy benefits in this dataset.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=M4h2j1b.SlSROEqKJ1oGMdkcdFaHmAh_uVL_q3b7crE-1787706180.8055089-1.2.1.1-pUZI4Vug9tQtipZDPqDnCR8spyiLZS3by551QNdj0TaVLE5gd28LzWFH_Itf6klz) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1) - a randomized, placebo-controlled phase IIa dose escalation trial targeting disease tolerance to infection Sebastian Weis, Luis Ferreira Moita, Daniel Thomas-Rueddel, Peter Schlattmann, Christiane Helbig, Thomas Lehmann, Patrick Meybohm, Sven-Olaf Kuhn, Tim Rahmel, Heiko Schenk, Brendan Tibbs, Thomas Koecher, Tiago Velho, Johannes Roth, Frank Brunkhorst, Markus Graeler, Ralf Claus, Johannes Ehler, Michael Bauer doi: https://doi.org/10.64898/2026.08.23.26360940 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Sebastian Weis 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sebastian%2BWeis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Weis%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASebastian%2BWeis%2B) * For correspondence: sebastian.weis@med.uni-jena.de Luis Ferreira Moita 2 Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Luis%2BFerreira%2BMoita%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Moita%20LF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALuis%2BFerreira%2BMoita%2B) Daniel Thomas-Rueddel 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BThomas-Rueddel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Thomas-Rueddel%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BThomas-Rueddel%2B) Peter Schlattmann 3 University Hospital Jena; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Peter%2BSchlattmann%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schlattmann%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APeter%2BSchlattmann%2B) Christiane Helbig 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christiane%2BHelbig%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Helbig%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristiane%2BHelbig%2B) Thomas Lehmann 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BLehmann%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lehmann%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BLehmann%2B) Patrick Meybohm 4 University Hospital Wuerzburg; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patrick%2BMeybohm%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Meybohm%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatrick%2BMeybohm%2B) Sven-Olaf Kuhn 5 Department of Anesthesiology, University Hospital of Greifswald, Greifswald, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sven-Olaf%2BKuhn%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kuhn%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASven-Olaf%2BKuhn%2B) Tim Rahmel 6 University Medical Center Knappschaftskrankenhaus Bochum; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tim%2BRahmel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rahmel%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATim%2BRahmel%2B) Heiko Schenk 7 MHH; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Heiko%2BSchenk%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schenk%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHeiko%2BSchenk%2B) Brendan Tibbs 8 University of Lisbon; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Brendan%2BTibbs%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tibbs%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABrendan%2BTibbs%2B) Thomas Koecher 9 Vienna BioCenter Core Facilities (VBCF) * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BKoecher%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Koecher%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BKoecher%2B) Tiago Velho 8 University of Lisbon; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tiago%2BVelho%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Velho%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATiago%2BVelho%2B) Johannes Roth 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Johannes%2BRoth%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Roth%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJohannes%2BRoth%2B) Frank Brunkhorst 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Frank%2BBrunkhorst%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brunkhorst%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFrank%2BBrunkhorst%2B) Markus Graeler 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Markus%2BGraeler%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Graeler%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarkus%2BGraeler%2B) Ralf Claus 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ralf%2BClaus%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Claus%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARalf%2BClaus%2B) Johannes Ehler 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Johannes%2BEhler%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ehler%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJohannes%2BEhler%2B) Michael Bauer 1 Jena University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BBauer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bauer%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BBauer%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1285958/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1285958/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1285958/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1285958/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1285958/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1285958/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Importance: Pharmacological targeting of host mechanisms that limit sepsis-induced organ dysfunction represents a new therapeutic approach. Preclinical studies showed that low-dose epirubicin enhances tissue damage control and attenuates sepsis severity independently of pathogen burden, thereby promoting disease tolerance to infection. Yet epirubicin can cause myelotoxicity when used in cancer therapy. Objective: To investigate whether low-dose epirubicin can safely be administered to patients with sepsis and septic shock. Design, Setting, and Participants: A randomized, double-blind, placebo-controlled clinical trial conducted in five German University hospitals. Patients with sepsis, defined by Sepsis-3 criteria, were eligible within 48 hours after diagnosis. The first patient was enrolled on October 19, 2022, and the last follow-up was conducted on May 21, 2025. Interventions: Eligible patients were randomized in a 4:1 ratio to receive either placebo or low-dose epirubicin in addition to standard care. There were three consecutive phases. Patients in the epirubicin group received a single dose of epirubicin (either 3.75 mg/m2, 7.5 mg/m2 or 15 mg/m2, depending on study phase). Main Outcomes and Measures: The primary endpoint of the trial was the 14-day myelotoxicity. Secondary and explorative outcomes included 90-day mortality, the degree of organ dysfunction as assessed by SOFA score, PK/PD modelling and cytokine release. Results: Of 854 patients assessed for eligibility, 32 were randomized and 31 were included in the primary analysis population. Six participants received placebo, nine participants received 3.75 mg/m2, nine received 7.5 mg/m2 and eight individuals received 15 mg/m2 epirubicin, respectively. There was no myelotoxicity in any group. Mortality at 90 days and SOFA-scores were not significantly different between groups. Two of 39 SAEs in the epirubicin group were assessed by the investigators as possibly related to epirubicin, Conclusions and Relevance Among patients with sepsis and septic shock, low dose epirubicin was not associated with increased myelotoxicity. ### Competing Interest Statement LFM is an inventor on an international patent (WO 2013/036153) related to the use of anthracyclines for sepsis treatment. All other authors report no competing interests ### Clinical Trial NCT05033808 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The trial was approved by the ethics committee of the Jena University Hospital on 20 December 2021 (2021-2440-AMG-ff) and the German Health Authorities (BfArM) on 08 November 2021. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors ## Funder Information Declared Bundesministerium für Forschung, Technologie und Raumfahrt, https://ror.org/04pz7b180, #01EN2001 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.22.26361118v1 "Work-related Musculoskeletal Pain Among Factory Workers in Kigali: Prevalence and Coping Strategies")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.23.26361143v1 "Paired plaque and plasma proteomics reveal molecular signatures of symptomatic atherosclerosis") Posted August 25, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/25/2026.08.23.26360940.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.23.26360940v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/25/2026.08.23.26360940.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1) - a randomized, placebo-controlled phase IIa dose escalation trial targeting disease tolerance to infection Sebastian Weis, Luis Ferreira Moita, Daniel Thomas-Rueddel, Peter Schlattmann, Christiane Helbig, Thomas Lehmann, Patrick Meybohm, Sven-Olaf Kuhn, Tim Rahmel, Heiko Schenk, Brendan Tibbs, Thomas Koecher, Tiago Velho, Johannes Roth, Frank Brunkhorst, Markus Graeler, Ralf Claus, Johannes Ehler, Michael Bauer medRxiv 2026.08.23.26360940; doi: https://doi.org/10.64898/2026.08.23.26360940 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.23.26360940v1%26text%3DEpirubicin%2520for%2520the%2520Treatment%2520of%2520Sepsis%2520and%2520Septic%2520Shock%2520%2528EPOS-1%2529%2520-%2520a%2520randomized%252C%2520placebo-controlled%2520phase%2520IIa%2520dose%2520escalation%2520trial%2520targeting%2520disease%2520tolerance%2520to%2520infection "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.23.26360940v1%26t%3DEpirubicin%2520for%2520the%2520Treatment%2520of%2520Sepsis%2520and%2520Septic%2520Shock%2520%2528EPOS-1%2529%2520-%2520a%2520randomized%252C%2520placebo-controll
## Related Clinical Research

- [Therapeutic coma in non‑convulsive status epilepticus: higher complications, longer ICU stay, and](https://medichelpline.com/clinical-feed/pubmed-42701136.md) (DOI: 10.1007/s00415-026-14090-8)
- [ePWV and delirium risk in ICU sepsis patients: retrospective MIMIC-IV analysis and predictive model](https://medichelpline.com/clinical-feed/pubmed-42700537.md) (DOI: 10.1016/j.clinsp.2026.101106)
- [Entropy-Based Framework to Quantify Dynamic Epistemic Uncertainty in Clinical LLM Reasoning](https://medichelpline.com/clinical-feed/medrxiv-1-novel-entropy-based-framework-for-quantifying-dynamic-epistemic-uncertainty-in.md)
- [Offline Reinforcement Learning for Out-of-Distribution ICU Sepsis Decision Support](https://medichelpline.com/clinical-feed/medrxiv-0-offline-reinforcement-learning-for-out-of-distribution-icu-sepsis-decision.md)
- [High AUROC can hide threshold failure in sepsis transcriptomic classifiers: preprocessing stabilit](https://medichelpline.com/clinical-feed/plos-one-13-high-auroc-can-mask-decision-failure-in-sepsis-transcriptomic-classifiers.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.